Preparing for Adolescent HIV Vaccine Trials in South Africa: (CATSA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00944879|
Recruitment Status : Unknown
Verified July 2009 by Desmond Tutu HIV Centre.
Recruitment status was: Not yet recruiting
First Posted : July 23, 2009
Last Update Posted : August 17, 2009
|Condition or disease|
|HIV Infection HIV Infections|
This study will use the licensed HPV vaccine, an alternative STI vaccine, as a proxy for an HIV vaccine and thereby identify potential challenges to the inclusion of adolescents in HIV prevention trials. The study will allow for site capacity building in terms of recruiting and retaining an HIV-negative high-risk adolescent cohort, and assessing the acceptability of an STI vaccine to adolescents and their parents or guardians. Correlates of vaccine uptake, refusal, retention and attrition will be determined. In addition, the study will document the incidence of HIV, other sexually transmitted infections (STI's) and pregnancies and circumcisions in this age group. Different methods of assessing understanding in adolescents will be tested, to ensure that informed consent is being achieved. Experiences of privacy and confidentiality issues for adolescents in such research will be explored. Finally, psycho-social correlates of sexual risk and protective behaviour will be examined.
The study is designed as a longitudinal cohort study with a self-selected intervention and control group. Adolescents and parents will be recruited through community outreach and invited to attend a Vaccine Discussion Group (VDG) to learn more about the HPV vaccine. Parental/ legal guardian consent and adolescent assent will be obtained prior to screening. After screening to ensure volunteers meet inclusion criteria, 1400 participants will be enrolled across seven sites. At this point, they will decide whether or not they want to receive the HPV vaccine. Those who do will receive three doses, at 0, 2 and 6 months. All participants will undergo HIV and pregnancy testing, receive risk reduction counseling and complete questionnaires at 0, 2, 6 and 9 months. Recruitment and retention will be monitored and data as described above will be collected throughout the course of the study.
|Study Type :||Observational|
|Estimated Enrollment :||1400 participants|
|Official Title:||Preparing for Adolescent HIV Vaccine Trials in South Africa: a Multi-centre Study to Evaluate Acceptability of the HPV Vaccine in Adolescents|
|Study Start Date :||August 2009|
|Estimated Primary Completion Date :||February 2011|
|Estimated Study Completion Date :||February 2011|
Those choosing to receive the HPV vaccine
no HPV vaccine
Those choosing not to receive the HPV vaccine
- Recruitment and retention [ Time Frame: 9 months ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00944879
|Desmond Tutu HIV Centre||Not yet recruiting|
|Cape Town, South Africa|
|Contact: Melissa L Wallace, MSc, PhD +27 21 650 6960 email@example.com|
|Contact: Agnes Ronan, RGN, MBA +27 21 650 6962 firstname.lastname@example.org|
|Principal Investigator: Linda-Gail Bekker, MBChB, PhD|
|Principal Investigator:||Linda-Gail Bekker, MBChB PhD||Desmond Tutu HIV Centre|